Bristol-Myers Squibb Announces Expiration of the Hart-Scott-Rodino Waiting Period for Acquisition of Amylin Pharmaceuticals, Inc.

Bristol-Myers Squibb Announces Expiration of the Hart-Scott-Rodino Waiting Period for Acquisition of Amylin Pharmaceuticals, Inc.

Jennifer Fron Mauer, 609-252-6579orLaura Hortas, 609-252-4587orTimothy Power, 609-252-7509

(NYSE: BMY) (“Bristol-Myers Squibb”) announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, as amended (HSR), for its tender offer for (NASDAQ: AMLN) (“Amylin”) has expired.

Bristol-Myers Squibb initiated on July 10, 2012, through its wholly-owned subsidiary B&R Acquisition Company, a cash tender offer to purchase all outstanding shares of common stock of Amylin for $31.00 per share.

The expiration of the HSR waiting period satisfies one of the conditions to the tender offer, which will expire at 5:00 PM (New York City time) on Tuesday, August 7, 2012, unless extended in accordance with the merger agreement and the applicable rules and regulations of the SEC. The closing of the tender offer is subject to customary terms and conditions, including there being validly tendered a number of shares that constitutes at least a majority of Amylin’s outstanding shares of common stock determined on a fully-diluted basis.

Georgeson, Inc. is acting as information agent for Bristol-Myers Squibb. Evercore Group L.L.C. and Citigroup Global Markets Inc. are serving as financial advisers to Bristol-Myers Squibb in connection with the acquisition and Kirkland & Ellis LLP is its legal adviser. Credit Suisse Securities (USA) LLC and Goldman, Sachs & Co. are serving as financial advisers to Amylin in connection with the acquisition and Skadden, Arps, Slate, Meagher & Flom LLP is its legal adviser.

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit or follow us on Twitter at .

Suggested Articles

NGM's aldafermin beat placebo at reversing liver scarring and inflammation, as well as reducing liver fat buildup in a 78-patient study.

The agreement sees Grifols waive a $32 million debt and pay $3 million in cash to take full ownership of three assets.

Astellas’ Xospata and Novartis’ Rydapt may help treat lung cancer that has grown resistant to EGFR inhibitors, researchers discovered.